A four-microRNA panel in serum may serve as potential biomarker for renal cell carcinoma diagnosis

• DOI: 10.3389/fonc.2022.1076303
• Publication Date: 2023-01-16T05:15:20Z
• Authors: Rongkang Li; Wenkang Chen; Chong Lu; Xinji Li; Xuan Chen; Guocheng Huang; Zhenyu Wen; Hang Li; Lingzhi Tao; Yimin Hu; Zhengping Zhao; Zebo Chen; Liangchao Ni; Yongqing Lai
• Keywords: renal cell carcinoma; microRNA; circulating biomarker; diagnosis; Neoplasms. Tumors. Oncology. Including cancer and carcinogens; bioinformatics; logistic regression model; 3. Good health; 03 medical and health sciences; 0302 clinical medicine; Oncology; RC254-282

Renal cell carcinoma (RCC) is one out of the most universal malignant tumors globally, and its incidence increasing annually. MicroRNA (miRNA) in serum could be considered as a non-invasive detecting biomarker for RCC diagnosis.A total 224 participants (112 patients (RCCs) 112 normal controls (NCs)) were enrolled three-phrase study. Reverse transcription quantitative PCR (RT-qPCR) was applied to reveal miRNA expression levels RCCs NCs. Receiver operating characteristic (ROC) curves area under ROC curve (AUC) utilized predict diagnostic ability miRNAs RCC. Bioinformatic analysis survival also included our study.Compared NCs, degree miR-155-5p, miR-224-5p significantly upregulated patients, miR-1-3p, miR-124-3p, miR-129-5p, miR-200b-3p downregulated. A four-miRNA panel construed, AUC 0.903 (95% CI: 0.847-0.944; p < 0.001; sensitivity = 75.61%, specificity 93.67%). Results from GEPIA database indicated that CHL1, MPP5, SORT1 seen promising target genes panel. Survival candidate manifested miR-155-5p associated with rate significantly.The has great potential biomarkers sift check.